title: PCR-RFLP typing of ureC from Helicobacter pylori isolated in Argentina from gastric biopsies before and after treatment with clarithromycin.
abstract: A clinical trial was conducted in Argentina to determine the efficacy of clarithromycin plus lansoprazole for the treatment of Helicobacter pylori in duodenal ulcers and non-ulcer dyspepsia. PCR-RFLP was conducted on an 820-bp amplified product of the ureC gene of H. pylori to determine the genetic heterogeneity of 83 pretreatment and 21 post-treatment isolates. Twelve different restriction patterns were observed when digested with Sau 3A or Hha I, resulting in 40 different RFLP types. Comparison of isolates before treatment to after treatment showed that 20 of 20 patients had the same RFLP type. In addition, the presence of the cytotoxin-associated gene (cagA) and the vacuolating gene (vacA) were determined. All pretreatment isolates were positive for vacA whereas 75% of the pretreatment isolates were positive for cagA. The results of this study indicate that a high degree of heterogeneity exists among H. pylori and that infection is not limited to a small number of RFLP types.
authors.affiliation: Anti-Infective Research Division, Abbott Laboratories, Abbott Park, Illinois 60064, USA.
authors.forename: G G
authors.initials: GG
authors.lastname: Stone
authors.forename: D
authors.initials: D
authors.lastname: Shortridge
authors.forename: R K
authors.initials: RK
authors.lastname: Flamm
authors.forename: J
authors.initials: J
authors.lastname: Beyer
authors.forename: D
authors.initials: D
authors.lastname: Stamler
authors.forename: S K
authors.initials: SK
authors.lastname: Tanaka
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000942:Antigens, Bacterial; D001426:Bacterial Proteins / Q000096:biosynthesis / Q000187:drug effects* / Q000235:genetics*; D001706:Biopsy; D017291:Clarithromycin / Q000627:therapeutic use*; D015342:DNA Probes; D005798:Genes, Bacterial / Q000187:drug effects*; D016481:Helicobacter Infections / Q000188:drug therapy / Q000382:microbiology*; D016480:Helicobacter pylori / Q000145:classification* / Q000235:genetics*; D006801:Humans; D016133:Polymerase Chain Reaction / Q000379:methods; D012150:Polymorphism, Restriction Fragment Length; D011500:Protein Synthesis Inhibitors / Q000627:therapeutic use*; D015203:Reproducibility of Results; D012703:Serotyping / Q000379:methods; D013272:Stomach Diseases / Q000188:drug therapy / Q000382:microbiology*
chemical_list: D000900:Anti-Bacterial Agents; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D015342:DNA Probes; D011500:Protein Synthesis Inhibitors; C074689:VacA protein, Helicobacter pylori; C080866:cagA protein, Helicobacter pylori; D017291:Clarithromycin